CFG
AVXL icon

Clayton Financial Group’s Anavex Life Sciences AVXL Stock Holding History

Clayton Financial Group’s Portfolio AVXL Stock Details AVXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-500
Closed -$1.53K – 106
2026
Q1 		$1.53K Hold
500
– – ﹤0.01% 510
2025
Q4 		$1.78K Buy
+500
New +$3.06K ﹤0.01% 477

Other funds holding AVXL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SF
Summit Financial Parsippany, New Jersey $9.12B AUM 27.44% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Clayton Financial Group's AVXL Position: Q2 2026 in Review

Clayton Financial Group sold out of Anavex Life Sciences (AVXL) in Q2 2026, closing a stake of 500 shares — an estimated $1.53K sold.

Clayton Financial Group first reported a position in AVXL in Q4 2025 and held it in 2 quarters. The position peaked at $1.78K in Q4 2025. 179 funds tracked by Wall St. Rank hold AVXL as of Q2 2026.

  • Clayton Financial Group reported no remaining Anavex Life Sciences position as of Q2 2026 after selling out during the quarter.
  • Clayton Financial Group sold 500 Anavex Life Sciences shares in Q2 2026, an estimated $1.53K.
  • Clayton Financial Group first reported a position in Anavex Life Sciences in Q4 2025 and held it in 2 quarters.
  • Clayton Financial Group's Anavex Life Sciences position peaked at $1.78K in Q4 2025.
  • 179 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q2 2026.

Based on Clayton Financial Group's 13F filing for Q2 2026, filed 20 Jul 2026.